Patients with type 2 diabetes are known to show raised serum levels of starch antigen 19âÂÃâÃâ¬ÂÃâÃÂ9 (CA 19âÂÃâÃâ¬ÂÃâÃÂ9). The point of the current examination was to research the potential connections of CA 19âÂÃâÃâ¬ÂÃâÃÂ9 with metabolic control, insulin obstruction (IR ), and pancreatic βâÂÃâÃâ¬ÂÃâÃÂcell work in patients with corpulence and type 2 diabetes who experienced RouxâÂÃâÃâ¬ÂÃâÃÂEnâÂÃâÃâ¬ÂÃâÃÂY gastric detour (RYGB ). verified that starch antigen 19âÂÃâÃâ¬ÂÃâÃÂ9 (CA19âÂÃâÃâ¬ÂÃâÃÂ9) is a tumorâÂÃâÃâ¬ÂÃâÃÂassociated antigen. CA19âÂÃâÃâ¬ÂÃâÃÂ9 was initially characterized by a monoclonal neutralizer created by a hybridoma arranged from murine spleen cells inoculated with a human colorectal malignancy cell line. In people, CA19âÂÃâÃâ¬ÂÃâÃÂ9 is communicated by the exocrine pancreas in vivo , and is raised in the blood of numerous patients with pancreatic diseases, malignancies of the upper gastrointestinal tract, ovarian malignant growth, hepatocellular malignant growth and colorectal cancer2. Besides, this antigen has a high incentive during the determination of pancreatic malignancy, since it has an affectability of 70–90% and a particularity of 68–91%3.